Holen Sie sich die Stockscreener-App
0.5204
5.43%
-0.0299
Handel nachbörslich:
.52
-0.0004
-0.08%
Schlusskurs vom Vortag:
$0.5503
Offen:
$0.532
24-Stunden-Volumen:
653.73K
Relative Volume:
0.55
Marktkapitalisierung:
$57.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.54M
KGV:
-0.3357
EPS:
-1.55
Netto-Cashflow:
$-18.30M
1W Leistung:
-8.70%
1M Leistung:
-13.27%
6M Leistung:
+63.70%
1J Leistung:
-67.48%
1-Tages-Spanne:
$0.52
$0.56
1-Wochen-Bereich:
$0.4501
$0.5796
52-Wochen-Spanne:
$0.202
$1.73
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Firmenname
Unicycive Therapeutics Inc
Sektor
Branche
Telefon
650-384-0642
Adresse
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Vergleichen Sie UNCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
0.5204 | 57.39M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-04 | Eingeleitet | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
Unicycive Therapeutics Inc (NASDAQ: UNCY) Is One Of The Hottest Stocks Right Now. - Stocks Register
Unicycive reports potential kidney disease treatment advance By Investing.com - Investing.com Nigeria
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 - The Manila Times
Unicycive reports potential kidney disease treatment advance - Investing.com
Unicycive Therapeutics Announces the Publication of - GlobeNewswire
Groundbreaking Kidney Disease Treatment Shows 41% Better ResultsCan This Change Dialysis Patient Care? - StockTitan
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 51.6% in January - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex
Investing in Unicycive Therapeutics Inc [UNCY]: What You Must Know - Knox Daily
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Is Expected To Breakeven In The Near Future - Simply Wall St
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Rises By 25.4% - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Gains Momentum, Closing at 0.61 - The Dwinnex
Unicycive Therapeutics' (UNCY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Unicycive highlights challenges in phosphate management - MSN
Unicycive Therapeutics Inc (UNCY) Has A Gold Mine On Its Hands - Stocks Register
Unicycive Therapeutics (NASDAQ:UNCY) Earns “Buy” Rating from HC Wainwright - Defense World
Unicycive Therapeutics Announces the Publication of Patient - GlobeNewswire
Unicycive highlights challenges in phosphate management By Investing.com - Investing.com Australia
Unicycive Therapeutics Publishes Review on Patient Perspectives in Phosphate Management for Chronic Kidney Disease - Nasdaq
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science - GlobeNewswire Inc.
Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation - Yahoo Finance
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update - MarketBeat
Unicycive Therapeutics’ (UNCY) Buy Rating Reiterated at HC Wainwright - Defense World
Unicycive Therapeutics Receives Notice of Non-Compliance from Nasdaq - Defense World
Unicycive Therapeutics (NASDAQ:UNCY) Receives "Buy" Rating from HC Wainwright - MarketBeat
Unicycive Therapeutics granted extension to meet Nasdaq compliance - Investing.com
Unicycive Therapeutics granted extension to meet Nasdaq compliance By Investing.com - Investing.com Canada
Unicycive reports positive phase 1 results for kidney drug By Investing.com - Investing.com Australia
Unicycive reports positive phase 1 results for kidney drug - Investing.com
Unicycive Therapeutics Announces Publication of Positive - GlobeNewswire
Unicycive's OLC Drug Shows Strong Safety Profile in Phase 1 Trial, FDA Decision Due 2025 - StockTitan
Unicycive Therapeutics Inc (NASDAQ: UNCY) Is A Safe Investment Now, Isn’t It? - Stocks Register
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics - The Manila Times
Unicycive Therapeutics Announces Publication of - GlobeNewswire
Unicycive Therapeutics (NASDAQ:UNCY) and Arvinas (NASDAQ:ARVN) Head-To-Head Review - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Decline in Short Interest - MarketBeat
Unicycive Therapeutics Inc (NASDAQ: UNCY): Overvalued In Comparison To Others? - Stocks Register
Analyzing Unicycive Therapeutics (NASDAQ:UNCY) and FibroGen (NASDAQ:FGEN) - Defense World
We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely - Simply Wall St
5,000,000 Shares in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Purchased by Walleye Capital LLC - MarketBeat
Acuta Capital Partners LLC Takes $807,000 Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - MarketBeat
Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Yahoo Finance
Great Point Partners LLC Takes $3.49 Million Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - MarketBeat
Unicycive's SWOT analysis: CKD treatment innovator's stock faces pivotal year - Investing.com India
Unicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46 - MSN
Unicycive Therapeutics (NASDAQ:UNCY) Receives "Speculative Buy" Rating from Benchmark - MarketBeat
Finanzdaten der Unicycive Therapeutics Inc-Aktie (UNCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):